ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
ALX ONCOLOGY HOLDINGS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.14+0.08 (+7.55%)
Close on Oct 19, 2026
- Market cap
- $154.63M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.36 (−24.00%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $154.63M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.14
- Dividend yield
- –
- Free cash flow yield
- -45.88%
Fundamentals
- Net income
- -$80.89M
- EPS, diluted
- -$1.13
- Free cash flow
- -$70.95M
- Book value per share
- $1.00
- Diluted shares
- 136M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$82.55M
Net income
-$80.89M
EPS, diluted
-$1.13
Free cash flow
-$70.95M
Reported periodTrailing twelve months